Home›Trial›NCT06906367
NCT06906367RECRUITING

A Study of Patients With Fabry Disease (US Specific)

Study Summary

This is an observational study to evaluate the effects of treatment on long-term effectiveness, safety, and health-related quality of life (HRQOL) in patients with Fabry disease, with a main focus on migalastat.

Conditions
Fabry Disease
Interventions / Drugs
migalastat HClERT
View on ClinicalTrials.gov ↗
Sponsor
FOLD
Amicus Therapeutics
Rare Disease
C57/100
Study Details
Enrollment450 participants
Primary Completion—
Lead SponsorAmicus Therapeutics
Data Retrieved2026-04-11 04:14:12.640574+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 450 participants
Sponsor Catalyst Profile

Amicus Therapeutics (FOLD) is the sponsoring company for this trial. BiotechSign currently grades this company C (57/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

FOLD Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.